Regorafenib in refractory gastric cancer: modest median, meaningful milestone.
0/5 보강
APA
Narita Y, Muro K (2026). Regorafenib in refractory gastric cancer: modest median, meaningful milestone.. Journal of gastrointestinal oncology, 17(1), 39. https://doi.org/10.21037/jgo-2025-728
MLA
Narita Y, et al.. "Regorafenib in refractory gastric cancer: modest median, meaningful milestone.." Journal of gastrointestinal oncology, vol. 17, no. 1, 2026, pp. 39.
PMID
41816593 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study.
- A prospective, multicenter, observational study of trastuzumab deruxtecan in elderly patients with HER2-positive gastric cancer: EN-COURAGE.
- Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study.
- Practical Management of Zolbetuximab Administration: The Project VYLOY Initiative.
- Systemic therapy strategies for elderly patients with gastric cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Tumor immune-vascular crosstalk: synergy and translation of immune checkpoint inhibitors and anti-angiogenic agents in melanoma.
- PrP-Neutralizing Antibody Confers an Additive Benefit in Combination with 5-Fluorouracil in KRAS-Mutant Colorectal Cancer Models, Associated with Reduced RAS-GTP and AKT/ERK Phosphorylation.
- Immune Checkpoint Inhibitor-Based Adjuvant Treatment Versus Surveillance in Curatively Treated Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis.
- Sohlh2 inhibited the angiogenesis of hepatocellular carcinoma through the HIF-1α/VEGFA pathway.
- Machine learning-based prognostic model of stemness and angiogenesis-related genes for predicting prognosis and immune infiltration in patients with HCC.
- Tumour endothelial cells in cancer: Chemo-physical crosstalk and angiogenic signalling in the tumour microenvironment.